Contract 75N94025F00001
Boston Medical Center Corporation · Department Of Health And Human Services · October 9, 2024
Boston Medical Center Corporation was awarded a federal contract by Department Of Health And Human Services (National Institutes Of Health) on October 9, 2024 for $16.89 million of work in research and development in biotechnology (except nanobiotechnology). Performance is in Boston, MA. This is a task or delivery order issued under parent IDIQ 75N94020D00004. The contract has been modified 82 times since the base award It uses cost no fee contract pricing. The most recent modification was on April 21, 2026.
Contract details
- PIID
- 75N94025F00001
- Parent IDIQ
- 75N94020D00004
- Award type
- Delivery Order
- Pricing
- Cost No Fee
- Competition
- Full And Open Competition
- NAICS
- 541714 · Research And Development In Biotechnology (Except Nanobiotechnology)
- Product / service
- Health R&D Services; Health Care Services; Applied Research
- Place of performance
- Boston, MA
- First action
- October 9, 2024
- Latest action
- April 21, 2026
Description
NICHD: R&D: A PHASE 2B STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SUBCUTANEOUS LEVONORGESTREL BUTANOATE FOR FEMALE CONTRACEPTION: NON-SEVERABLE
Modification timeline
-
April 21, 2026Mod P00002$499.9K
-
April 21, 2026Mod P00002$514.7K
-
April 1, 2026Mod P00001NICHD:R&D:DATA COORDINATING CENTER FOR THE FOLLOW-UP OF THE SECOND PHASE (COHORT 2) OF THE PRENATAL AND CHILDHOOD MECHANISMS OF HEALTH DISPARITIES OBSERVATIONAL$292.3K
-
February 23, 2026Mod P00001NICHD: R&D: COORDINATION, MONITORING, FOLLOW-UP, EVALUATION, AND COMPLETION OF A CLINICAL TRIAL OF NESTORONE TESTOSTERONE GEL FOR MALE CONTRACEPTION: NON-SEVERA$358.1K
-
January 30, 2026Mod P00001NICHD: R&D: A PHASE 2B STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SUBCUTANEOUS LEVONORGESTREL BUTANOATE FOR FEMALE CONTRACEPTION: SEVERABLE$0
-
January 30, 2026Mod P00001NICHD: SERVICE: CCTN LB PHASE 2B CLINICAL TRIAL: NON-SEVERABLE$0
-
January 29, 2026Mod P00001NICHD: SERVICE: CCTN LB PHASE 2B CLINICAL TRIAL: NON-SEVERABLE$0
-
January 28, 2026Mod P00001NICHD: R&D: TO EVALUATE IN OBESE AND NON-OBESE WOMEN THE PHARMACOKINETICS (PK), PHARMACODYNAMIC (PD) EFFECTS, SAFETY, AND CONTRACEPTIVE EFFICACY OF LEVONORGESTR$0
-
January 28, 2026Mod P00001NICHD: SERVICE: CCTN LB PHASE 2B CLINICAL TRIAL: NON-SEVERABLE$0
-
January 26, 2026Mod P00001$0
Similar contracts
| Recipient | Agency | Date | Obligated |
|---|---|---|---|
| Vericel Corporation | Department Of Health And Human Services | April 1, 2026 | $34.88M |
| Ceramedix Holding, Llc | Department Of Health And Human Services | March 31, 2026 | $4.22M |
| American College Of Medical Toxicology, Inc. | Department Of Health And Human Services | March 31, 2026 | $0 |
| Glaxosmithkline, Llc | Department Of Health And Human Services | March 31, 2026 | $7.79M |
| Care Access Research Llc | Department Of Health And Human Services | March 31, 2026 | $2.55M |
| Pattern Bioscience, Inc. | Department Of Health And Human Services | March 31, 2026 | $22.50M |
Top contractors in NAICS 541714
Lifetime obligated dollars across all federal contracts in this NAICS code.
| # | Contractor | Contracts | Obligated |
|---|---|---|---|
| 1 | The Boeing Company | 1 | $4.44B |
| 2 | Advanced Technology International | 9 | $3.35B |
| 3 | Amgen USA Inc | 2 | $774.69M |
| 4 | Siga Technologies, Inc. | 1 | $624.44M |
| 5 | Icon Government And Public Health Solutions, Inc. | 16 | $404.80M |
| 6 | Technical Resources International, Inc. | 19 | $395.29M |
| 7 | Allucent Government Services (Us) Llc | 9 | $384.26M |
| 8 | Mapp Biopharmaceutical, Inc. | 7 | $354.24M |
| 9 | Ppd Development Lp | 18 | $331.02M |
| 10 | Albert B. Sabin Vaccine Institute, Inc. (The) | 2 | $305.87M |
Track this on BesaGov
Get a free weekly email when this changes — new awards, new sub-awards, new opportunities. No login required.
Continue learning
Keep researching
Frequently asked questions
What is contract 75N94025F00001?
Contract 75N94025F00001 is a federal contract awarded to Boston Medical Center Corporation by Department Of Health And Human Services on October 9, 2024 for $16.89 million of work classified under RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY). It has been modified 82 times since the base award.
Who won contract 75N94025F00001?
Boston Medical Center Corporation won contract 75N94025F00001 from Department Of Health And Human Services.
How much is contract 75N94025F00001 worth?
Contract 75N94025F00001 has obligated $16.89 million to date.